Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer

• Status: Unknown status
• Trial end date: 2021-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigator's study is a single armed phrase II trial ,aiming to improve the effecacy of treatment for advanced billiary tract cancer by means of Toripalimab combining with S1 and Albumin Paclitaxel as first line in patients with advanced Biliary Tract Cancer. treatment continually until disease progression or intolerable toxicity or Patients withdrawal of consent.and target sample is 30+ patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dai, Guanghai
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel

Criteria

Inclusion Criteria:

1. Age ≥ 18 years old

2. Patients with gallbladder and cholangiocarcinoma diagnosed by histology or cytology

3. Liver function Child-Pugh grade A (5-6 points) or better grade B (≤ 7 points)

4. ECOG score 0 or 1 point

5. At least one measurable lesion

6. no previous treatment

Exclusion Criteria:

1. organs failure ,including liver ,heart ,kidney

2. Have received a liver transplant in the past

3. Active brain metastasis or spinal cord compression

4. ECOG score 3 or 4 point

5. Symptomatic peripheral neuropathy (CTCAE ≥ 2)